Stocks · News reference
electroCore, Inc. announced it will release its financial results for the third quarter ended September 30, 2026, after market close on November 4, 2026.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
electroCore, Inc. has submitted a 510(k) premarket notification to the FDA seeking clearance for its Quell wearable neuromodulation platform to treat chronic chemotherapy-induced peripheral neuropathy.
Ecora Royalties reported its Q3 2026 trading results, highlighting a portfolio contribution of $24.8 million and continued progress in deleveraging its balance sheet.
electroCore, Inc. reported findings from a controlled fMRI study conducted by the U.S. Air Force Research Laboratory evaluating the impact of transcutaneous cervical vagus nerve stimulation on visual skill learning.